论文部分内容阅读
目的：观察阿克拉霉素（Ａｃ）、阿糖胞苷（Ａ）组成的联合化疗方案对急性非淋巴细胞白血病（ＡＮＬＬ）的临床疗效。方法：用ＡｃＡ方案治疗ＡＮＬＬ４７例，其中初治４０例，复发及难治７ 例，Ｍ１ ８例，Ｍ２ １７例，Ｍ４ ３ 例，Ｍ５ １１例，Ｍ６ ８例，观察临床疗效及药物毒副作用，与ＡＮＬＬ治疗的标准诱导方案ＤＡ（柔红霉素、阿糖胞苷）方案比较。结果：完全缓解率５９．６％ （２８／４７），部分缓解率８．５％ （４／４７），总有效率６８．１％ 。毒副作用：均出现骨髓抑制，无明显心、肝、肾毒性。结论：ＡｃＡ方案完全缓解率与ＤＡ方案相当，但毒副作用较ＤＡ方案小，且对复发难治病例有效，可为临床作为诱导缓解方案，广泛用于ＡＮＬＬ的治疗。
OBJECTIVE: To observe the clinical efficacy of combined chemotherapy regimens of aclarubicin (Ac) and cytarabine (A) on acute nonlymphocytic leukemia (ANLL). Methods: 47 patients with ANLL were treated with AcA regimen. Among them, 40 patients were initially treated, 7 patients were relapsed and refractory, 7 patients were M1, 17 patients were M2, 3 patients were M4, 11 patients were M5, 8 patients were M6. Clinical efficacy and drug side effects were observed. Comparison with the standard induction program DA (daunorubicin, cytarabine) protocol for the treatment of ANLL. Results: The complete remission rate was 59.6% (28/47), the partial remission rate was 8.5% (4/47), and the total effective rate was 68.1%. The toxic and side effects: bone marrow suppression occurred, no significant heart, liver and kidney toxicity. Conclusion: The complete remission rate of AcA is similar to that of DA, but its toxicity is smaller than that of DA, and it is effective for relapsed and refractory cases. It can be used as an induction remission protocol and widely used in the treatment of ANLL.